story of the week
Survival Outcomes Following Palbociclib Plus Aromatase Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
NPJ breast cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer
NPJ Breast Cancer 2022 Oct 11;8(1)114, HS Rugo, A Brufsky, X Liu, B Li, L McRoy, C Chen, RM Layman, M Cristofanilli, MA Torres, G Curigliano, RS Finn, A DeMicheleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.